



Astec LifeSciences Ltd.

Dated: 5th May, 2020

To,
BSE Limited
P. J. Towers, Dalal Street, Fort
Mumbai – 400 001

To,
National Stock Exchange of India Limited
Exchange Plaza, Bandra - Kurla Complex,
Bandra (East), Mumbai-400 051

Ref.: BSE Scrip Code No. "533138"

Ref.: "ASTEC"

Sub.: Outcome of the Board Meeting

Pursuant to Regulations 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") read with Schedule III to the said Regulations, this is to inform you that the Board of Directors of the Company, at its Meeting held today, i.e., on Tuesday, 5th May, 2020 (which commenced at 4.00 p.m. and concluded at 5.50 p.m.), *inter alia*, has approved / noted the following:-

- (a) Upon recommendation of the Audit Committee, the Board of Directors has approved the Audited Financial Results (Standalone & Consolidated) as per Indian Accounting Standards (IND AS) for the Quarter and Financial Year ended 31st March, 2020 along with Cash Flow Statement and the Statement of Assets and Liabilities as on 31st March, 2020 (enclosed herewith).
- (b) Upon recommendation of the Audit Committee, took note of the Statutory Auditors' Report on the Audited Financial Results (Standalone & Consolidated) for the Quarter and Financial Year ended 31st March, 2020 (enclosed herewith).

The Report of Statutory Auditors is with unmodified opinion with respect to the Audited Financial Results (Standalone and Consolidated) of the Company for the Quarter and Financial Year ended 31st March, 2020.

- (c) Recommended Final Dividend of 15% (Fifteen per cent) on the Equity Share Capital of the Company, i.e., Rs.1.50 (Rupee One and Paise Fifty) per Equity Share of Face Value of Rs.10/- (Rupees Ten Only) each for the Financial Year ended 31st March, 2020, subject to approval of the Shareholders at the ensuing 26th (Twenty Sixth) Annual General Meeting of the Company.
- (d) Considered and fixed the date of the 26th (Twenty Sixth) Annual General Meeting and related matters as under:-
 - (i) The 26th (Twenty Sixth) Annual General Meeting of the Shareholders of the Company will be held on Wednesday, 22nd July, 2020 at 4.00 p.m. at the "Auditorium", Godrej One, Pirojshanagar, Eastern Express Highway, Vikhroli (East), Mumbai – 400079, Maharashtra.



Regd. Office :
"Godrej One", 3rd Floor,
Pirojshanagar, Eastern Express Highway,
Vikhroli (East), Mumbai-400079,
Maharashtra, India
Telephone No.: 022- 25188010
Fax No.: 022-22618289
Email id: astecinfo@godrejastec.com
Website: www.astecsls.com
CIN : L99999MH1994PLC076236

(ii) The Book Closure Dates for the purposes of the 26th (Twenty Sixth) Annual General Meeting and payment of Final Dividend are from Saturday, 18th July, 2020 to Tuesday, 21st July, 2020. The dividend will be paid by Friday, 31st July, 2020.

(iii) The Register of Members and Share Transfer Books will remain closed from Saturday, 18th July, 2020 to Tuesday, 21st July, 2020.

(e) The Board of Directors has amended the Code of Conduct for Prevention of Insider Trading of the Company.

(f) Re-appointment of Mr. Vijay Kashinath Khot and Dr. Brahma Nand Vyas as the “Independent Directors” of the Company – Intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“said Regulations”) read with Para A of Part A of Schedule III to the said Regulations:

The Board of Directors has, upon the recommendation of the Nomination and Remuneration Committee of the Board of Directors of the Company, re-appointed Mr. Vijay Kashinath Khot and Dr. Brahma Nand Vyas as the “Independent Director” of the Company for a further period of 5 (five) years commencing from 29th January, 2021 upto 28th January, 2026, subject to approval of the Shareholders at the ensuing Annual General Meeting of the Company and other approval(s), as may be required.

Disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“said Regulations”) read with Para A of Part A of the Schedule III to the said Regulations, with regard to change in Directors and Key Managerial Personnel is given hereunder:-

Sr. No.	Disclosure Requirement	Mr. Vijay Kashinath Khot	Dr. Brahma Nand Vyas
1.	Reason for Change, viz., appointment, resignation, removal, death or otherwise	The present term of Mr. Vijay Kashinath Khot as an “Independent Director” of the Company is expiring on 28 th January, 2021. The Board of Directors has granted approval for his re-appointment as an “Independent Director” of the Company for a further period of 5 (Five) years commencing from 29 th January, 2021 upto 28 th January, 2026, for a second	The present term of Dr. Brahma Nand Vyas as an “Independent Director” of the Company is expiring on 28 th January, 2021. The Board of Directors has granted approval for his re-appointment as an “Independent Director” of the Company for a further period of 5 (Five) years commencing from 29 th January, 2021 upto 28 th January, 2026, subject to

		term, subject to approval of the Shareholders in the ensuing Annual General Meeting of the Company and other approval(s), as may be required.	approval of the Shareholders in the ensuing Annual General Meeting of the Company and other approval(s), as may be required.
2.	Date of appointment / cessation (as applicable) and term of appointment	Upon recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company, at its Meeting held today, i.e., on Tuesday, 5 th May, 2020, has re-appointed Mr. Vijay Kashinath Khot as the “Independent Director” of the Company for a further period of 5 (Five) years commencing from 29 th January, 2021 upto 28 th January, 2026, for a second term, subject to approval of the Shareholders in the ensuing Annual General Meeting of the Company and other approval(s), as may be required.	Upon recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company, at its Meeting held today, i.e., on Tuesday, 5 th May, 2020, has re-appointed Dr. Brahma Nand Vyas as the “Independent Director” of the Company for a further period of 5 (Five) years commencing from 29 th January, 2021 upto 28 th January, 2026, for a second term, subject to approval of the Shareholders in the ensuing Annual General Meeting of the Company and other approval(s), as may be required.
3.	Brief Profile (in case of appointment)	Mr. Vijay Kashinath Khot, aged 70 years, is Science Graduate from the University of Mumbai and was associated with Godrej Group from September 1973 till 2011. He has worked in Animal Feeds for 26 years in the State of Gujarat and was also instrumental in introducing Godrej Agri Products in the said State in the year 1986. Since the year	Dr. Brahma Nand Vyas, aged 70 years, has completed graduation B.Sc. Agriculture in 1971 from the University of Rajasthan, Jaipur and Post-Graduation M.Sc. Agriculture with Honours in Soil Science and Agricultural Chemistry in 1973 from the University of Udaipur, Rajasthan. He worked with Bhabha Atomic Research Centre (BARC) Trombay, since 1974 till 1987, and then joined Godrej Soaps Limited.

		<p>2000, he was associated with Poultry business and was looking after the sales of Real Good Chicken (RGC) mainly in the metro cities of Mumbai, Pune, Bangalore, Chennai and Hyderabad. He was also a Director of Bahar Agrochem And Feeds Limited, Goldmuhor Agrochem & Feeds Limited and Anamudi Real Estates Limited. As a trainer, he imparts training to sales personnel in his professional capacity.</p>	<p>He obtained Doctorate in 1980, while in service in Chemistry from University of Gujarat, Ahmedabad. At BARC, Dr. Vyas worked on the Behavioural aspects of most Toxic Radionuclides Plutonium -239 and Americium-241 in soils and Soil-Plant systems.</p> <p>At Godrej Soaps Limited initially and later at Godrej Agrovet Limited, he led R&D for nearly two decades, and was responsible for the development and Launch of first ever Commercial Neem based Urea Coating Agent, the country's first CIB Registered Neem Insecticide, the world's first Homobrassinolide based Growth Promoters for grapes initially and later for other crops, and most recently very Unique Post Emergence Selective Herbicide for Cotton, based on Pyriithiobac sodium. During the R&D assignments, he has published more than 60 scientific publications in International and National Journals of High repute, besides presentations at International Seminars. He is the holder of more than 25 patents including international patents.</p>
4.	Disclosure of relationships between the Directors (in case of appointment of Director)	Mr. Vijay Kashinath Khot is not related to any other Director of the Company.	Dr. Brahma Nand Vyas is not related to any other Director of the Company.



Astec LifeSciences Ltd.

Further, this is to confirm that Vijay Kashinath Khot and Dr. Brahma Nand Vyas are not debarred from holding the office of Director by virtue of any order of the Securities and Exchange Board of India (SEBI) or any other such authority.

Please take the above information on your records.

Thanking you,

Yours sincerely,

For Astec LifeSciences Limited

Tejashree Pradhan
Company Secretary & Compliance Officer
(FCS 7167)

Encl.: As above



Regd. Office :
"Godrej One", 3rd Floor,
Pirojshanagar, Eastern Express Highway,
Vikhroli (East), Mumbai-400079,
Maharashtra, India
Telephone No.: 022- 25188010
Fax No.: 022-22618289
Email id: astecinfo@godrejastec.com
Website: www.astecsl.com
CIN : L99999MH1994PLC076236

Rs. in Lakh (Except per Equity Share data)

Sr. No	Particulars	STANDALONE				
		Quarter Ended			Year Ended	
		31-Mar-20	31-Dec-19	31-Mar-19	31-Mar-20	31-Mar-19
		(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
I	Revenue from Operations	18,018.43	12,483.36	13,375.79	52,222.09	43,090.12
II	Other Income	524.15	393.09	574.04	1,193.25	1,110.07
III	Total Income (I+II)	18,542.58	12,876.45	13,949.83	53,415.34	44,200.19
IV	Expenses					
	Cost of materials consumed	10,117.40	9,015.27	6,431.98	33,343.71	29,505.18
	Changes in inventories of finished goods, stock-in-trade and work-in-progress	1,066.10	(1,002.22)	2,819.82	472.50	(1,555.88)
	Employee benefits expense	860.05	746.65	565.55	2,992.04	2,509.88
	Finance costs	215.99	339.38	315.17	1,263.88	1,237.59
	Depreciation and amortisation expense	616.37	579.15	547.46	2,322.38	1,934.06
	Other expenses (Refer note 7)	1,705.55	1,639.10	1,252.09	6,893.41	4,990.03
	Total expenses (IV)	14,581.46	11,317.33	11,932.07	47,287.92	38,620.86
V	Profit / (loss) before exceptional items and tax (III - IV)	3,961.12	1,559.12	2,017.76	6,127.42	5,579.33
VI	Exceptional Items	-	-	-	-	-
VII	Profit / (loss) before tax (V + VI)	3,961.12	1,559.12	2,017.76	6,127.42	5,579.33
VIII	Tax Expense:					
	(1) Current tax	1,047.74	402.48	472.87	1,605.78	1,528.88
	(2) Deferred tax	(203.24)	(74.38)	244.91	(305.49)	442.22
	(3) Tax for earlier years	-	15.60	30.05	79.94	39.63
IX	Profit / (loss) for the period from continuing operations (VII-VIII)	3,116.62	1,215.42	1,269.93	4,747.19	3,568.60
X	Profit / (loss) from discontinued operations	-	-	-	-	-
XI	Tax expense of discontinued operations	-	-	-	-	-
XII	Profit / (loss) from Discontinued operations (after tax) (X-XI)	-	-	-	-	-
XIII	Profit / (loss) for the period (IX + XII)	3,116.62	1,215.42	1,269.93	4,747.19	3,568.60
XIV	Other Comprehensive Income					
	A (i) Items that will not be reclassified to profit or loss	(19.31)	(1.68)	3.80	(24.34)	(6.70)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	4.87	0.42	(1.33)	6.13	2.34
	B (i) Items that will be reclassified to profit or loss	-	-	49.18	-	35.25
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	(17.07)	-	(12.20)
XV	Total Comprehensive Income for the period (XIII + XIV) (Comprising Profit / (loss) and Other Comprehensive Income for the period)	3,102.18	1,214.16	1,304.51	4,728.98	3,587.29
XVI	Paid-up Equity Share Capital (Face Value of Rs.10/- per share)	1,956.84	1,956.56	1,955.27	1,956.84	1,955.27
XVII	Other Equity excluding Revaluation Reserve				22,687.06	18,291.22
XVIII	Earnings per equity share (Face Value of Rs.10/- per share) (for continuing & discontinued operations) (non-annualised) :					
	(1) Basic (in Rs.)	15.94	6.21	6.50	24.27	18.26
	(2) Diluted (in Rs.)	15.93	6.21	6.49	24.25	18.23

Notes:

- 1 The above Financial Results which are published in accordance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations & Disclosure Requirements) Regulations, 2015 have been reviewed by the Audit Committee and have been approved by the Board of Directors at its Meeting held on Tuesday, 5th May, 2020.
- 2 The Financial Results are in accordance with the Indian Accounting Standards (Ind-AS) as prescribed under section 133 of the Companies Act ("Act"), read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 (including any amendment(s) / modification(s) / re-enactment(s) thereto). The Financial Results have been subjected to an audit by the Statutory Auditors of the Company and they have expressed an unmodified audit opinion.
- 3 The Company has only one reportable segment i.e. Agrochemicals as per Ind-AS 108 "Operating Segments" specified under Section 133 of the Companies Act, 2013.
- 4 The figures for the Quarter ended 31st March, 2020 and 31st March, 2019 are the balancing figures between audited figures in respect of the full Financial Year and the published unaudited Year To Date figures upto the end of the third Quarter of the relevant Financial Year.
- 5 The Board of Directors have recommended Final Dividend of 15% of Equity Share Capital of the Company, i.e. Rs. 1.50 per Equity Share of Face Value of Rs. 10/- each for the Financial Year ended 31st March, 2020, subject to approval of the Shareholders at the ensuing 26th Annual General Meeting of the Company.
- 6 In March 2020, the World Health Organisation (WHO) declared COVID-19 a pandemic. The Company has adopted measures to curb the spread of infection in order to protect the health of our employees and ensure business continuity with minimal disruption.
- In assessing the recoverability of receivables and other financial assets, the company has considered internal and external information upto the date of approval of these financial results. The impact of the global health pandemic may be different from that estimated as at the date of approval of these financial results and the company will continue to closely monitor any material changes to future economic conditions.
- 7 Other expenses for "Year ended 31st March, 2020" includes Rs.620.09 Lakhs in respect of a classification error of export incentives claimed in earlier years for certain products exported by the Company.
- 8 Effective 1st April, 2019, the Company has adopted Ind-AS 116 "Leases" using modified retrospective approach. This has resulted in recognizing right of use assets and lease liability as on 1st April, 2019. The adoption of the standard did not have any material impact on the financial results.

For Astec LifeSciences Limited

ASHOK

VISHWANATH

HIRENMATH

Ashok Hiremath

Managing Director

DIN :- 00349345

Tuesday, 5th May, 2020, Mumbai

BURJIS

TEHMURASP

PARDIWAL A

Digitally signed by

BURJIS TEHMURASP

PARDIWALA
Date: 2020.05.05

17:31:53 ±05'30'



Astec LifeSciences Limited

Corporate Identity Number : L99999MH1994PLC076236

Registered Office : Godrej One, 3rd Floor, Pirojshanagar, Eastern Express Highway, Vikhroli (East), Mumbai- 400079, Maharashtra

Website: www.astecsl.com, Tel no.: 022-2519 5768, Fax no.: 022-2261 8289, Email id: astecinvestors@godrejastec.com

Statement of Audited Consolidated Financial Results for the Quarter and Year ended 31st March, 2020



Rs. in Lakh (Except per Equity Share data)

Sr. No	Particulars	CONSOLIDATED				
		Quarter Ended			Year Ended	
		31-Mar-20	31-Dec-19	31-Mar-19	31-Mar-20	31-Mar-19
		(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
I	Revenue from Operations	18,056.95	12,483.36	13,375.79	52,260.61	43,090.12
II	Other Income	524.15	393.09	575.94	1,193.25	1,115.66
III	Total Income (I+II)	18,581.10	12,876.45	13,951.73	53,453.86	44,205.78
IV	Expenses					
	Cost of materials consumed	10,117.40	9,015.27	6,431.98	33,343.71	29,505.18
	Purchase of Stock-in-Trade	37.07	-	-	37.07	-
	Changes in inventories of finished goods, stock-in-trade and work-in-progress	1,066.10	(1,002.22)	2,819.82	472.50	(1,555.88)
	Employee benefits expense	860.05	746.65	565.55	2,992.04	2,509.88
	Finance costs	214.88	338.27	315.17	1,259.43	1,237.59
	Depreciation and amortisation expense	614.88	577.66	547.68	2,316.42	1,934.94
	Other expenses (Refer note 7)	1,707.45	1,639.81	1,249.97	6,897.44	4,983.66
	Total expenses (IV)	14,617.83	11,315.44	11,930.17	47,318.61	38,615.37
V	Profit / (loss) before exceptional items and tax (III - IV)	3,963.27	1,561.01	2,021.56	6,135.25	5,590.41
VI	Exceptional Items	-	-	-	-	-
VII	Profit / (loss) before tax (V + VI)	3,963.27	1,561.01	2,021.56	6,135.25	5,590.41
VIII	Tax Expense:					
	(1) Current tax	1,048.07	402.90	473.69	1,607.40	1,530.88
	(2) Deferred tax	(203.01)	(74.22)	245.20	(304.80)	442.94
	(3) Tax for previous years	-	15.60	30.05	79.94	40.05
IX	Profit / (loss) for the period from continuing operations (VII-VIII)	3,118.21	1,216.73	1,272.62	4,752.71	3,576.54
X	Profit / (loss) from discontinued operations	-	-	-	-	-
XI	Tax expense of discontinued operations	-	-	-	-	-
XII	Profit / (loss) from Discontinued operations (after tax) (X-XI)	-	-	-	-	-
XIII	Profit / (loss) for the period (IX + XII)	3,118.21	1,216.73	1,272.62	4,752.71	3,576.54
XIV	Other Comprehensive Income					
	A (i) Items that will not be reclassified to profit or loss	(19.31)	(1.68)	3.80	(24.34)	(6.70)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	4.87	0.42	(1.33)	6.13	2.34
	B (i) Items that will be reclassified to profit or loss	1.26	(0.73)	49.15	1.15	36.01
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	(17.07)	-	(12.20)
XV	Total Comprehensive Income for the period (XIII + XIV) (Comprising Profit / (loss) and Other Comprehensive Income for the period)	3,105.03	1,214.74	1,307.17	4,735.65	3,595.99
XVI	Net Profit/(loss) attributable to:					
	- Owners	3,117.61	1,216.39	1,271.78	4,751.11	3,573.68
	- Non controlling interests	0.60	0.34	0.84	1.60	2.86
	Total Comprehensive Income attributable to:					
	- Owners	3,104.43	1,214.40	1,306.33	4,734.05	3,593.13
	- Non controlling interests	0.60	0.34	0.84	1.60	2.86
XVII	Paid-up Equity Share Capital (Face Value of Rs. 10/- per share)	1,956.84	1,956.56	1,955.27	1,956.84	1,955.27
XVIII	Other Equity excluding Revaluation Reserve	-	-	-	22,699.74	18,293.38
XIX	Earnings per equity share (Face Value of Rs. 10/- per share) (for continuing & discontinued operations) (non-annualised) :					
	(1) Basic (in Rs.)	15.94	6.22	6.50	24.29	18.28
	(2) Diluted (in Rs.)	15.93	6.21	6.50	24.27	18.26

Notes:

- The above Financial Results which are published in accordance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations & Disclosure Requirements) Regulations, 2015 have been reviewed by the Audit Committee and have been approved by the Board of Directors at its Meeting held on Tuesday, 5th May, 2020.
- The Financial Results are in accordance with the Indian Accounting Standards (Ind-AS) as prescribed under section 133 of the Companies Act ("Act"), read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 (including any amendment(s) / modification(s) / re-enactment(s) thereto). The Financial Results have been subjected to an audit by the Statutory Auditors of the Company and they have expressed an unmodified audit opinion.
- The Company has only one reportable segment i.e. Agrochemicals as per Ind-AS 108 "Operating Segments" specified under Section 133 of the Companies Act, 2013.
- The figures for the Quarter ended 31st March, 2020 and 31st March, 2019 are the balancing figures between audited figures in respect of the full Financial Year and the published unaudited Year To Date figures upto the end of the third Quarter of the relevant Financial Year.
- The Board of Directors have recommended Final Dividend of 15% of Equity Share Capital of the Company, i.e. Rs. 1.50 per Equity Share of Face Value of Rs. 10/- each for the Financial Year ended 31st March, 2020, subject to approval of the Shareholders at the ensuing 26th Annual General Meeting of the Company.
- In March 2020, the World Health Organisation (WHO) declared COVID-19 a pandemic. The Company has adopted measures to curb the spread of infection in order to protect the health of our employees and ensure business continuity with minimal disruption.
In assessing the recoverability of receivables and other financial assets, the company has considered internal and external information upto the date of approval of these financial results. The impact of the global health pandemic may be different from that estimated as at the date of approval of these financial results and the company will continue to closely monitor any material changes to future economic conditions.
- Other expenses for "Year ended 31st March, 2020" includes Rs.620.09 Lakhs in respect of a classification error of export incentives claimed in earlier years for certain products exported by the Company.
- Effective 1st April, 2019, the Company has adopted Ind-AS 116 "Leases" using modified retrospective approach. This has resulted in recognizing right of use assets and lease liability as on 1st April, 2019. The adoption of the standard did not have any material impact on the financial results.

For Astec LifeSciences Limited

ASHOK
VISHWANATH
HIRENMATH

Digital Signature of Ashok Hirenmath
2020.05.05 17:32:19 +05'30'

Ashok Hirenmath
Managing Director
DIN :- 00349345

Tuesday, 5th May, 2020, Mumbai

BURJIS
TEHMURASP
PARDIWALA

Digitally signed by
BURJIS TEHMURASP
PARDIWALA
Date: 2020.05.05
17:32:19 +05'30'



Corporate Identity Number : L99999MH1994PLC076236

Website: www.astecls.com, **Tel no.:** 022-25195768, **Fax no.:** 022-22618289, **Email id:** astecinfo@godrejastec.com

Statement of Cash Flows for the Year ended 31st March, 2020



(Rs. in Lakh)

	STANDALONE		CONSOLIDATED	
	Year Ended		Year Ended	
<u>PARTICULARS</u>	31-Mar-20	31-Mar-19	31-Mar-20	31-Mar-19
	(Audited)	(Audited)	(Audited)	(Audited)
Cash flow from operating activities				
Profit before tax	6,127.42	5,579.33	6,135.25	5,590.41
Adjustments for				
Depreciation and amortisation expense	2,321.89	1,934.06	2,316.42	1,934.94
Interest income	(26.56)	(36.28)	(26.56)	(36.28)
Finance cost	1,263.88	1,237.59	1,259.43	1,237.59
Unrealised foreign exchange (gain)/loss	142.74	(189.76)	143.89	(189.00)
Loss allowance	31.14	3.58	31.14	3.58
Loss/(Gain) on sale of property, plant and equipment	17.96	(0.04)	17.96	(0.04)
Bad debts / advances written off	-	242.54	-	242.54
Employee stock options expense	5.55	16.35	5.55	16.35
Net loss / (Gain) on lease modification	0.48	-	-	-
Sundry balances written back	-	(174.75)	-	(174.75)
	3,757.08	3,033.29	3,747.83	3,034.93
Operating Profit Before Working Capital Changes	9,884.50	8,612.62	9,883.08	8,625.34
Change in operating assets and liabilities				
(Increase)/Decrease in trade receivables	(3,437.45)	(102.89)	(3,437.53)	(102.86)
(Increase)/Decrease in loans	1.77	(52.85)	1.77	(52.85)
(Increase)/Decrease in other financial assets-current	(430.63)	91.08	(430.63)	91.08
(Increase)/Decrease in other current assets	1,741.49	(431.51)	1,741.69	(431.52)
(Increase)/Decrease in inventories	(2,832.11)	(1,437.12)	(2,832.11)	(1,437.12)
(Increase)/Decrease in other non-current assets	38.40	(12.77)	38.40	(12.77)
Increase/(Decrease) in trade payables	13,124.53	(3,514.01)	13,115.25	(3,554.97)
Increase/(Decrease) in other financial liabilities	547.45	19.37	547.15	52.15
Increase/(Decrease) in other current liabilities	35.44	8.99	35.91	2.43
Increase/(Decrease) in provisions	2.76	(7.90)	2.76	(7.90)
Cash generated from operations	18,676.15	3,173.01	18,665.74	3,171.01
Direct Taxes paid (net of refunds received)	(1,820.03)	(1,640.51)	(1,821.68)	(1,642.46)
Net cash inflow / (outflow) operating activities	16,856.12	1,532.50	16,844.06	1,528.55
Cash flow from investing activities				
Acquisition of property, plant and equipment & cwip	(4,529.40)	(5,277.54)	(4,529.40)	(5,277.54)
Proceeds from sale of property, plant and equipment	15.75	1.61	15.75	1.61
Intercompany deposits given	(2,886.52)	-	(2,886.52)	-
Deposits redeemed / (placed)	10.98	(10.27)	10.98	(10.27)
Interest received	8.12	36.28	8.12	36.28
Net cash inflow / (outflow) investing activities	(7,381.07)	(5,249.92)	(7,381.06)	(5,249.92)
Cash flow from financing activities				
Proceeds / (Repayment) of borrowings (net)	(7,830.73)	5,272.93	(7,830.73)	5,272.93
Proceeds from issue of shares	21.96	27.60	21.96	27.60
Payment of lease liabilities	(10.80)	-	-	-
Finance cost	(1,291.03)	(1,237.59)	(1,291.03)	(1,237.59)
Dividend paid to company's shareholders (including Dividend Distribution Tax)	(353.63)	(353.45)	(353.63)	(353.45)
Net cash inflow (outflow) from financing activities	(9,464.23)	3,709.49	(9,453.43)	3,709.48
Net increase / (decrease) in cash and cash equivalents	10.82	(7.93)	9.58	(11.89)
Cash and cash equivalents as at the beginning of the year	16.44	24.37	21.23	33.12
Cash and cash equivalents as at the end of the year	27.26	16.44	30.81	21.23

ASHOK
VISHWANATH
HIRENMATH

Digitally signed by ASHOK VISHWANATH
HIRENMATH
DN: cn=, o=Personal,
2.5.4.20=30ce7081e5bf507f2334966d2dec
b96413f56c3ba731cc480fb9587e646,
postalCode=400005, st=MAHARASHTRA,
serialNumber=2b2c693b3875c046230b6b
0bc97b7949c5272051d8aeb086d636879
c67e, cn=ASHOK VISHWANATH HIRENMATH
Date: 2007.05.05 16:48:00 +0330

BURJIS
TEHMURASP
PARDIWALA

Digitally signed by
BURJIS TEHMURASP
PARDIWALA
Date: 2020.05.05
17:32:44 +05'30'



Astec LifeSciences Limited
Corporate Identity Number : L99999MH1994PLC076236

Registered Office : Godrej One, 3rd Floor, Pirojshanagar, Eastern Express Highway, Vikhroli (East), Mumbai- 400079, Maharashtra

Website: www.astecsl.com, Tel no.-022-25195768, Fax no.- 022-22618289, Email id: astecinfo@godrejastec.com

Statement of Assets and Liabilities as at 31st March, 2020



(Rs. in Lakh)

PARTICULARS	STANDALONE		CONSOLIDATED	
	As at 31st March, 2020 (Audited)	As at 31st March, 2019 (Audited)	As at 31st March, 2020 (Audited)	As at 31st March, 2019 (Audited)
ASSETS				
(1) Non-current assets				
(a) Property, Plant and Equipment	17,747.43	16,457.64	17,772.40	16,488.23
(b) Capital work-in-progress	2,211.22	1,863.24	2,211.22	1,863.24
(c) Investment property	-	-	-	-
(d) Right of use	1,463.75	-	1,433.17	-
(e) Other Intangible assets	156.86	206.71	156.86	206.71
(f) Intangible assets under development	199.52	34.74	199.52	34.74
(g) Biological Assets other than bearer plants	-	-	-	-
(h) Investments in Subsidiaries	48.89	48.89	-	-
(g) Financial Assets				
(i) Investments	0.53	0.53	0.53	0.53
(ii) Trade receivables	-	-	-	-
(ii) Loans	244.28	245.25	254.40	255.37
(ii) Others	-	-	-	-
(h) Other Tax assets (net)	351.55	217.24	351.55	217.21
(h) Deferred tax assets (net)	-	-	-	-
(i) Other non-current assets	1,617.07	2,194.42	1,617.07	2,194.42
Total Non-current assets	24,041.10	21,268.66	23,996.72	21,260.45
(2) Current Assets				
(a) Inventories	12,117.06	9,284.95	12,117.06	9,284.95
(b) Financial Assets				
(i) Investments	-	-	-	-
(ii) Trade Receivables	16,083.06	12,179.58	16,084.49	12,180.93
(iii) Cash and cash equivalents	27.26	16.44	30.81	21.23
(iv) Bank balances other than (iii) above	117.97	126.90	117.97	126.90
(v) Loans	2,890.57	4.85	2,890.57	4.85
(vi) Others	473.35	26.34	473.35	26.34
(c) Other current assets	1,459.38	3,200.87	1,460.87	3,202.56
Total Current Assets	33,168.65	24,839.93	33,175.12	24,847.76
Total Assets	57,209.75	46,108.59	57,171.84	46,108.21
EQUITY AND LIABILITIES				
Equity				
(a) Equity Share capital	1,956.84	1,955.27	1,956.84	1,955.27
(b) Other Equity	22,687.06	18,291.22	22,699.74	18,293.38
(c) Non controlling interest	-	-	32.85	31.25
Total Equity	24,643.90	20,246.49	24,689.43	20,279.90
LIABILITIES				
(1) Non-current liabilities				
(a) Financial Liabilities				
(i) Lease liability	36.16	-	-	-
(b) Provisions	32.02	22.86	32.02	22.86
(c) Deferred tax liabilities (net)	609.50	922.95	614.10	925.02
Total Non Current Liabilities	677.68	945.81	646.12	947.88
(2) Current Liabilities				
(a) Financial Liabilities				
(i) Borrowings	9,871.16	17,566.79	9,871.16	17,566.79
(ii) Trade payables				
Total outstanding dues from Micro, Small and Medium Enterprises	11.91	102.64	11.91	102.64
Total outstanding dues from other than Micro, Small and Medium Enterprises	20,275.10	6,261.58	20,227.05	6,222.80
(iii) Other financial liabilities	1,584.37	893.03	1,579.06	894.94
(b) Other current liabilities	91.20	55.76	92.68	56.77
(c) Provisions	54.43	36.49	54.43	36.49
Total Current Liabilities	31,888.17	24,916.29	31,836.29	24,880.43
Total Equity and Liabilities	57,209.75	46,108.59	57,171.84	46,108.21

For Astec LifeSciences Limited

ASHOK
VISHWANATH
HIRENMATH

Ashok Hiremath
Managing Director
DIN :- 00349345
Tuesday, 5th May, 2020, Mumbai

BURJIS
TEHMURASP
PARDIWALA

Digitally signed by
BURJIS TEHMURASP
PARDIWALA
Date: 2020.05.05
17:33:11 +05'30'

B S R & Co. LLP

Chartered Accountants

5th Floor, Lodha Excelus,
Apollo Mills Compound
N. M. Joshi Marg, Mahalaxmi
Mumbai - 400 011
India

Telephone +91 (22) 4345 5300
Fax +91 (22) 4345 5399

Independent Auditors' Report

To The Board of Directors of Astec LifeSciences Limited.

Report on the audit of the Standalone Annual Financial Results

Opinion

We have audited the accompanying standalone annual financial results of Astec LifeSciences Limited Company Limited (hereinafter referred to as the "Company") for the year ended 31 March 2020, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone annual financial results:

- a. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- b. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards, and other accounting principles generally accepted in India, of the net profit and other comprehensive income and other financial information for the year ended 31 March 2020.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those SAs are further described in the *Auditor's Responsibilities for the Audit of the Standalone Annual Financial Results* section of our report. We are independent of the Company, in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act, and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained, is sufficient and appropriate to provide a basis for our opinion on the Standalone annual financial results.

Management's and Board of Directors' Responsibilities for the Standalone Annual Financial Results

These standalone annual financial results have been prepared on the basis of the standalone annual financial statements.

Independent Auditors' Report (*Continued*)

Astec LifeSciences Limited.

Management's and Board of Directors' Responsibilities for the Standalone Annual Financial Results (*Continued*)

The Company's Management and the Board of Directors are responsible for the preparation and presentation of these standalone annual financial results that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standards prescribed under Section 133 of the Act and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone annual financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone annual financial results, the Management and the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Annual Financial Results

Our objectives are to obtain reasonable assurance about whether the standalone annual financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone annual financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone annual financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of financial statements on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.

Independent Auditors' Report (*Continued*)

Astec LifeSciences Limited.

Auditor's Responsibilities for the Audit of the Standalone Annual Financial Results (*Continued*)

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures in the standalone financial results made by the Management and Board of Directors.
- Conclude on the appropriateness of the Management and Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the appropriateness of this assumption. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone annual financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone annual financial results, including the disclosures, and whether the standalone annual financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matters

The standalone annual financial results include the results for the quarter ended 31 March 2020 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

For B S R & Co. LLP

Chartered Accountants

Firm's Registration No: 101248W/W-100022

BURJIS

TEHMURASP

PARDIWALA

Digitally signed by
BURJIS TEHMURASP
PARDIWALA
Date: 2020.05.05
17:26:56 +05'30'

Burjis Pardiwala

Partner

Mumbai

5 May 2020

Membership Number: 103595

UDIN: 20103595AAAABE9353

B S R & Co. LLP

Chartered Accountants

5th Floor, Lodha Excelus,
Apollo Mills Compound
N. M. Joshi Marg, Mahalaxmi
Mumbai - 400 011
India

Telephone +91 (22) 4345 5300
Fax +91 (22) 4345 5399

Independent Auditors' Report

To The Board of Directors of Astec LifeSciences Limited

Report on the audit of the Consolidated Annual Financial Results

Opinion

We have audited the accompanying consolidated annual financial results of Astec LifeSciences Limited (hereinafter referred to as the "Holding Company") and its subsidiaries (Holding Company and its subsidiaries together referred to as "the Group") for the year ended 31 March 2020, attached herewith, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us and based on the consideration of report of other auditors on separate audited financial statements / financial information of the subsidiaries referred to in other matters paragraph below, the aforesaid consolidated annual financial results:

- a. include the annual financial results/ financial information of the following entities:
 - i. Behram Chemicals Private Limited
 - ii. Astec Europe SPRL
 - iii. Comercializadora Agricola Agroastrachem CIA LTDA
- b. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- c. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards, and other accounting principles generally accepted in India, of consolidated net profit and other comprehensive income and other financial information of the Group for the year ended 31 March 2020.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those SAs are further described in the *Auditor's Responsibilities for the Audit of the Consolidated Annual Financial Results* section of our report. We are independent of the Group in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act, and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us along with the consideration of audit reports of the other auditors referred to in sub paragraph (a) of the "Other Matters" paragraph below, is sufficient and appropriate to provide a basis for our opinion on the consolidated annual financial results.

Independent Auditors' Report (*Continued*)

Astec LifeSciences Limited

Management's and Board of Directors' Responsibilities for the Consolidated Annual Financial Results

These consolidated annual financial results have been prepared on the basis of the consolidated annual financial statements.

The Holding Company's Management and the Board of Directors are responsible for the preparation and presentation of these consolidated annual financial results that give a true and fair view of the consolidated net profit and other comprehensive income and other financial information of the Group in accordance with the recognition and measurement principles laid down in Indian Accounting Standards prescribed under Section 133 of the Act and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The respective Management and Board of Directors of the companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of each company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the consolidated annual financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated annual financial results by the Management and the Directors of the Holding Company, as aforesaid.

In preparing the consolidated annual financial results, the Management and the respective Board of Directors of the companies included in the Group are responsible for assessing the ability of each company to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the company or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group is responsible for overseeing the financial reporting process of each company.

Auditor's Responsibilities for the Audit of the Consolidated Annual Financial Results

Our objectives are to obtain reasonable assurance about whether the consolidated annual financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated annual financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated annual financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

Independent Auditors' Report (*Continued*)

Astec LifeSciences Limited

Auditor's Responsibilities for the Audit of the Consolidated Annual Financial Results (*Continued*)

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of financial statements on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures in the consolidated financial results made by the Management and Board of Directors.
- Conclude on the appropriateness of the Management and Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the appropriateness of this assumption. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated annual financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated annual financial results, including the disclosures, and whether the consolidated annual financial results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial results/financial information of the entities within the Group to express an opinion on the consolidated annual financial results. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the consolidated financial results of which we are the independent auditors. For the other entities included in the consolidated annual financial results, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion. Our responsibilities in this regard are further described in para (a) of the section titled "Other Matters" in this audit report.

We communicate with those charged with governance of the Holding Company and such other entities included in the consolidated annual financial results of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the circular No CIR/CFD/CMD1/44/2019 issued by the SEBI under Regulation 33(8) of the Listing Regulations, as amended, to the extent applicable.

Independent Auditors' Report (*Continued*)

Astec LifeSciences Limited

Other Matters

- (a) The consolidated annual financial results include the audited financial results of a subsidiary, whose financial results reflect total assets (before consolidation adjustments) of Rs.103.34 Lakhs as at 31 March 2020, total revenue (before consolidation adjustments) of Rs.10.80 Lakhs and total net profit after tax (before consolidation adjustments) of Rs. 6.24 Lakhs and net cash inflows of Rs 0.00 Lakhs for the year ended on that date, as considered in the consolidated annual financial results, which have been audited by their independent auditors. The independent auditors' report on financial results of this entity has been furnished to us by the management and our opinion on the consolidated annual financial results, in so far as it relates to the amounts and disclosures included in respect of this entity, is based solely on the report of such auditors and the procedures performed by us are as stated in paragraph above.
- (b) The consolidated annual financial results include the unaudited financial information of two subsidiaries, whose financial information reflect total assets (before consolidation adjustments) of Rs. 5.72 Lakhs as at 31 March 2020, total revenue (before consolidation adjustments) of Rs. 38.52 Lakhs and total net (loss) after tax (before consolidation adjustments) of Rs. (1.09) lakhs, and net cash (outflows) of Rs. (1.24) Lakhs for the year ended on that date, as considered in the consolidated annual financial results. These unaudited financial information have been furnished to us by the Board of Directors and our opinion on the consolidated annual financial results, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on such financial information. In our opinion and according to the information and explanations given to us by the Board of Directors, these financial information are not material to the Group.
- Our opinion on the consolidated annual financial results is not modified in respect of the above matters with respect to our reliance on the work done and the report of the other auditors and the financial information certified by the Board of Directors.
- (c) The consolidated annual financial results include the results for the quarter ended 31 March 2020 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

For **B S R & Co. LLP**

Chartered Accountants

Firm's Registration No: 101248W/W-100022

BURJIS
TEHMURASP
PARDIWALA
Digitally signed by
BURJIS TEHMURASP
PARDIWALA
Date: 2020.05.05
17:30:27 +05'30'

Burjis Pardiwala

Partner

Mumbai
5 May 2020

Membership No: 103595
UDIN: 20103595AAAABF8002

**MACHINE
READABLE
AND
SEARCHABLE
FORMAT**



Astec LifeSciences Limited

Corporate Identity Number : L99999MH1994PLC076236

Registered Office : Godrej One, 3rd Floor, Pirojshanagar, Eastern Express Highway, Vikhroli (East), Mumbai- 400079, Maharashtra

Website: www.astecsl.com, Tel no.: 022-2519 5768, Fax no.: 022-2261 8289, Email id: astecinvestors@godrejastec.com

Statement of Audited Standalone Financial Results for the Quarter and Year ended 31st March, 2020



Rs. in Lakh (Except per Equity Share data)

Sr. No	Particulars	STANDALONE				
		Quarter Ended		Year Ended		
		31-Mar-20 (Audited)	31-Dec-19 (Unaudited)	31-Mar-19 (Audited)	31-Mar-20 (Audited)	31-Mar-19 (Audited)
I	Revenue from Operations	18,018.43	12,483.36	13,375.79	52,222.09	43,090.12
II	Other Income	524.15	393.09	574.04	1,193.25	1,110.07
III	Total Income (I+II)	18,542.58	12,876.45	13,949.83	53,415.34	44,200.19
IV	Expenses					
	Cost of materials consumed	10,117.40	9,015.27	6,431.98	33,343.71	29,505.18
	Changes in inventories of finished goods, stock-in-trade and work-in-progress	1,066.10	(1,002.22)	2,819.82	472.50	(1,555.88)
	Employee benefits expense	860.05	746.65	565.55	2,992.04	2,509.88
	Finance costs	215.99	339.38	315.17	1,263.88	1,237.59
	Depreciation and amortisation expense	616.37	579.15	547.46	2,322.38	1,934.06
	Other expenses (Refer note 7)	1,705.55	1,639.10	1,252.09	6,893.41	4,990.03
	Total expenses (IV)	14,581.46	11,317.33	11,932.07	47,287.92	38,620.86
V	Profit / (loss) before exceptional items and tax (III - IV)	3,961.12	1,559.12	2,017.76	6,127.42	5,579.33
VI	Exceptional Items	-	-	-	-	-
VII	Profit / (loss) before tax (V + VI)	3,961.12	1,559.12	2,017.76	6,127.42	5,579.33
VIII	Tax Expense:					
	(1) Current tax	1,047.74	402.48	472.87	1,605.78	1,528.88
	(2) Deferred tax	(203.24)	(74.38)	244.91	(305.49)	442.22
	(3) Tax for earlier years	-	15.60	30.05	79.94	39.63
IX	Profit / (loss) for the period from continuing operations (VII-VIII)	3,116.62	1,215.42	1,269.93	4,747.19	3,568.60
X	Profit / (loss) from discontinued operations	-	-	-	-	-
XI	Tax expense of discontinued operations	-	-	-	-	-
XII	Profit / (loss) from Discontinued operations (after tax) (X-XI)	-	-	-	-	-
XIII	Profit / (loss) for the period (IX + XII)	3,116.62	1,215.42	1,269.93	4,747.19	3,568.60
XIV	Other Comprehensive Income					
	A (i) Items that will not be reclassified to profit or loss	(19.31)	(1.68)	3.80	(24.34)	(6.70)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	4.87	0.42	(1.33)	6.13	2.34
	B (i) Items that will be reclassified to profit or loss	-	-	49.18	-	35.25
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	(17.07)	-	(12.20)
XV	Total Comprehensive Income for the period (XIII + XIV) (Comprising Profit / (loss) and Other Comprehensive Income for the period)	3,102.18	1,214.16	1,304.51	4,728.98	3,587.29
XVI	Paid-up Equity Share Capital (Face Value of Rs.10/- per share)	1,956.84	1,956.56	1,955.27	1,956.84	1,955.27
XVII	Other Equity excluding Revaluation Reserve				22,687.06	18,291.22
XVIII	Earnings per equity share (Face Value of Rs.10/- per share) (for continuing & discontinued operations) (non-annualised) :					
	(1) Basic (in Rs.)	15.94	6.21	6.50	24.27	18.26
	(2) Diluted (in Rs.)	15.93	6.21	6.49	24.25	18.23

Notes:

- The above Financial Results which are published in accordance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations & Disclosure Requirements) Regulations, 2015 have been reviewed by the Audit Committee and have been approved by the Board of Directors at its Meeting held on Tuesday, 5th May, 2020.
- The Financial Results are in accordance with the Indian Accounting Standards (Ind-AS) as prescribed under section 133 of the Companies Act ("Act"), read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 (including any amendment(s) / modification(s) / re-enactment(s) thereto). The Financial Results have been subjected to an audit by the Statutory Auditors of the Company and they have expressed an unmodified audit opinion.
- The Company has only one reportable segment i.e. Agrochemicals as per Ind-AS 108 "Operating Segments" specified under Section 133 of the Companies Act, 2013.
- The figures for the Quarter ended 31st March, 2020 and 31st March, 2019 are the balancing figures between audited figures in respect of the full Financial Year and the published unaudited Year To Date figures upto the end of the third Quarter of the relevant Financial Year.
- The Board of Directors have recommended Final Dividend of 15% of Equity Share Capital of the Company, i.e. Rs. 1.50 per Equity Share of Face Value of Rs. 10/- each for the Financial Year ended 31st March, 2020, subject to approval of the Shareholders at the ensuing 26th Annual General Meeting of the Company.
- In March 2020, the World Health Organisation (WHO) declared COVID-19 a pandemic. The Company has adopted measures to curb the spread of infection in order to protect the health of our employees and ensure business continuity with minimal disruption.
In assessing the recoverability of receivables and other financial assets, the company has considered internal and external information upto the date of approval of these financial results. The impact of the global health pandemic may be different from that estimated as at the date of approval of these financial results and the company will continue to closely monitor any material changes to future economic conditions.
- Other expenses for "Year ended 31st March, 2020" includes Rs.620.09 Lakhs in respect of a classification error of export incentives claimed in earlier years for certain products exported by the Company.
- Effective 1st April, 2019, the Company has adopted Ind-AS 116 "Leases" using modified retrospective approach. This has resulted in recognizing right of use assets and lease liability as on 1st April, 2019. The adoption of the standard did not have any material impact on the financial results.

For Astec LifeSciences Limited

Ashok Hiremath

Managing Director

DIN :- 00349345

Tuesday, 5th May, 2020, Mumbai



Astec LifeSciences Limited

Corporate Identity Number : L99999MH1994PLC076236

Registered Office : Godrej One, 3rd Floor, Pirojshanagar, Eastern Express Highway, Vikhroli (East), Mumbai- 400079, Maharashtra

Website: www.astecsl.com, Tel no.: 022-2519 5768, Fax no.: 022-2261 8289, Email id: astecinvestors@godrejastec.com

Statement of Audited Consolidated Financial Results for the Quarter and Year ended 31st March, 2020



Rs. in Lakh (Except per Equity Share data)

Sr. No	Particulars	CONSOLIDATED				
		Quarter Ended			Year Ended	
		31-Mar-20	31-Dec-19	31-Mar-19	31-Mar-20	31-Mar-19
		(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
I	Revenue from Operations	18,056.95	12,483.36	13,375.79	52,260.61	43,090.12
II	Other Income	524.15	393.09	575.94	1,193.25	1,115.66
III	Total Income (I+II)	18,581.10	12,876.45	13,951.73	53,453.86	44,205.78
IV	Expenses					
	Cost of materials consumed	10,117.40	9,015.27	6,431.98	33,343.71	29,505.18
	Purchase of Stock-in-Trade	37.07	-	-	37.07	-
	Changes in inventories of finished goods, stock-in-trade and work-in-progress	1,066.10	(1,002.22)	2,819.82	472.50	(1,555.88)
	Employee benefits expense	860.05	746.65	565.55	2,992.04	2,509.88
	Finance costs	214.88	338.27	315.17	1,259.43	1,237.59
	Depreciation and amortisation expense	614.88	577.66	547.68	2,316.42	1,934.94
	Other expenses (Refer note 7)	1,707.45	1,639.81	1,249.97	6,897.44	4,983.66
	Total expenses (IV)	14,617.83	11,315.44	11,930.17	47,318.61	38,615.37
V	Profit / (loss) before exceptional items and tax (III - IV)	3,963.27	1,561.01	2,021.56	6,135.25	5,590.41
VI	Exceptional Items	-	-	-	-	-
VII	Profit / (loss) before tax (V + VI)	3,963.27	1,561.01	2,021.56	6,135.25	5,590.41
VIII	Tax Expense:					
	(1) Current tax	1,048.07	402.90	473.69	1,607.40	1,530.88
	(2) Deferred tax	(203.01)	(74.22)	245.20	(304.80)	442.94
	(3) Tax for previous years	-	15.60	30.05	79.94	40.05
IX	Profit / (loss) for the period from continuing operations (VII-VIII)	3,118.21	1,216.73	1,272.62	4,752.71	3,576.54
X	Profit / (loss) from discontinued operations	-	-	-	-	-
XI	Tax expense of discontinued operations	-	-	-	-	-
XII	Profit / (loss) from Discontinued operations (after tax) (X-XI)	-	-	-	-	-
XIII	Profit / (loss) for the period (IX + XII)	3,118.21	1,216.73	1,272.62	4,752.71	3,576.54
XIV	Other Comprehensive Income					
	A (i) Items that will not be reclassified to profit or loss	(19.31)	(1.68)	3.80	(24.34)	(6.70)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	4.87	0.42	(1.33)	6.13	2.34
	B (i) Items that will be reclassified to profit or loss	1.26	(0.73)	49.15	1.15	36.01
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	(17.07)	-	(12.20)
XV	Total Comprehensive Income for the period (XIII + XIV) (Comprising Profit / (loss) and Other Comprehensive Income for the period)	3,105.03	1,214.74	1,307.17	4,735.65	3,595.99
XVI	Net Profit/(loss) attributable to:					
	- Owners	3,117.61	1,216.39	1,271.78	4,751.11	3,573.68
	- Non controlling interests	0.60	0.34	0.84	1.60	2.86
	Total Comprehensive Income attributable to:					
	- Owners	3,104.43	1,214.40	1,306.33	4,734.05	3,593.13
	- Non controlling interests	0.60	0.34	0.84	1.60	2.86
XVII	Paid-up Equity Share Capital (Face Value of Rs.10/- per share)	1,956.84	1,956.56	1,955.27	1,956.84	1,955.27
XVIII	Other Equity excluding Revaluation Reserve	-	-	-	22,699.74	18,293.38
XIX	Earnings per equity share (Face Value of Rs.10/- per share) (for continuing & discontinued operations) (non-annualised) :					
	(1) Basic (in Rs.)	15.94	6.22	6.50	24.29	18.28
	(2) Diluted (in Rs.)	15.93	6.21	6.50	24.27	18.26

Notes:

- The above Financial Results which are published in accordance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations & Disclosure Requirements) Regulations, 2015 have been reviewed by the Audit Committee and have been approved by the Board of Directors at its Meeting held on Tuesday, 5th May, 2020.
- The Financial Results are in accordance with the Indian Accounting Standards (Ind-AS) as prescribed under section 133 of the Companies Act ("Act"), read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 (including any amendment(s) / modification(s) / re-enactment(s) thereto). The Financial Results have been subjected to an audit by the Statutory Auditors of the Company and they have expressed an unmodified audit opinion.
- The Company has only one reportable segment i.e. Agrochemicals as per Ind-AS 108 "Operating Segments" specified under Section 133 of the Companies Act, 2013.
- The figures for the Quarter ended 31st March, 2020 and 31st March, 2019 are the balancing figures between audited figures in respect of the full Financial Year and the published unaudited Year To Date figures upto the end of the third Quarter of the relevant Financial Year.
- The Board of Directors have recommended Final Dividend of 15% of Equity Share Capital of the Company, i.e. Rs. 1.50 per Equity Share of Face Value of Rs. 10/- each for the Financial Year ended 31st March, 2020, subject to approval of the Shareholders at the ensuing 26th Annual General Meeting of the Company.
- In March 2020, the World Health Organisation (WHO) declared COVID-19 a pandemic. The Company has adopted measures to curb the spread of infection in order to protect the health of our employees and ensure business continuity with minimal disruption.
In assessing the recoverability of receivables and other financial assets, the company has considered internal and external information upto the date of approval of these financial results. The impact of the global health pandemic may be different from that estimated as at the date of approval of these financial results and the company will continue to closely monitor any material changes to future economic conditions.
- Other expenses for "Year ended 31st March, 2020" includes Rs.620.09 Lakhs in respect of a classification error of export incentives claimed in earlier years for certain products exported by the Company.
- Effective 1st April, 2019, the Company has adopted Ind-AS 116 "Leases" using modified retrospective approach. This has resulted in recognizing right of use assets and lease liability as on 1st April, 2019. The adoption of the standard did not have any material impact on the financial results.

For Astec LifeSciences Limited

Ashok Hiremath
Managing Director
DIN :- 00349345
Tuesday, 5th May, 2020, Mumbai



Astec LifeSciences Limited

Corporate Identity Number : L99999MH1994PLC076236

Registered Office : Godrej One, 3rd Floor, Pirojshanagar, Eastern Express Highway, Vikhroli (East), Mumbai- 400079, Maharashtra

Website: www.astecsl.com, Tel no.:022-25195768, Fax no.: 022-22618289, Email id: astecinfo@godrejastec.com

Statement of Cash Flows for the Year ended 31st March, 2020



(Rs. in Lakh)

PARTICULARS	STANDALONE		CONSOLIDATED	
	Year Ended		Year Ended	
	31-Mar-20 (Audited)	31-Mar-19 (Audited)	31-Mar-20 (Audited)	31-Mar-19 (Audited)
Cash flow from operating activities				
Profit before tax	6,127.42	5,579.33	6,135.25	5,590.41
Adjustments for				
Depreciation and amortisation expense	2,321.89	1,934.06	2,316.42	1,934.94
Interest income	(26.56)	(36.28)	(26.56)	(36.28)
Finance cost	1,263.88	1,237.59	1,259.43	1,237.59
Unrealised foreign exchange (gain)/loss	142.74	(189.76)	143.89	(189.00)
Loss allowance	31.14	3.58	31.14	3.58
Loss/(Gain) on sale of property, plant and equipment	17.96	(0.04)	17.96	(0.04)
Bad debts / advances written off	-	242.54	-	242.54
Employee stock options expense	5.55	16.35	5.55	16.35
Net loss / (Gain) on lease modification	0.48	-	-	-
Sundry balances written back	-	(174.75)	-	(174.75)
	3,757.08	3,033.29	3,747.83	3,034.93
Operating Profit Before Working Capital Changes	9,884.50	8,612.62	9,883.08	8,625.34
Change in operating assets and liabilities				
(Increase)/Decrease in trade receivables	(3,437.45)	(102.89)	(3,437.53)	(102.86)
(Increase)/Decrease in loans	1.77	(52.85)	1.77	(52.85)
(Increase)/Decrease in other financial assets-current	(430.63)	91.08	(430.63)	91.08
(Increase)/Decrease in other current assets	1,741.49	(431.51)	1,741.69	(431.52)
(Increase)/Decrease in inventories	(2,832.11)	(1,437.12)	(2,832.11)	(1,437.12)
(Increase)/Decrease in other non-current assets	38.40	(12.77)	38.40	(12.77)
Increase/(Decrease) in trade payables	13,124.53	(3,514.01)	13,115.25	(3,554.97)
Increase/(Decrease) in other financial liabilities	547.45	19.37	547.15	52.15
Increase/(Decrease) in other current liabilities	35.44	8.99	35.91	2.43
Increase/(Decrease) in provisions	2.76	(7.90)	2.76	(7.90)
Cash generated from operations	18,676.15	3,173.01	18,665.74	3,171.01
Direct Taxes paid (net of refunds received)	(1,820.03)	(1,640.51)	(1,821.68)	(1,642.46)
Net cash inflow / (outflow) operating activities	16,856.12	1,532.50	16,844.06	1,528.55
Cash flow from investing activities				
Acquisition of property, plant and equipment & cwip	(4,529.40)	(5,277.54)	(4,529.40)	(5,277.54)
Proceeds from sale of property, plant and equipment	15.75	1.61	15.75	1.61
Intercompany deposits given	(2,886.52)	-	(2,886.52)	-
Deposits redeemed / (placed)	10.98	(10.27)	10.98	(10.27)
Interest received	8.12	36.28	8.12	36.28
Net cash inflow / (outflow) investing activities	(7,381.07)	(5,249.92)	(7,381.06)	(5,249.92)
Cash flow from financing activities				
Proceeds / (Repayment) of borrowings (net)	(7,830.73)	5,272.93	(7,830.73)	5,272.93
Proceeds from issue of shares	21.96	27.60	21.96	27.60
Payment of lease liabilities	(10.80)	-	-	-
Finance cost	(1,291.03)	(1,237.59)	(1,291.03)	(1,237.59)
Dividend paid to company's shareholders (including Dividend Distribution Tax)	(353.63)	(353.45)	(353.63)	(353.45)
Net cash inflow (outflow) from financing activities	(9,464.23)	3,709.49	(9,453.43)	3,709.48
Net increase / (decrease) in cash and cash equivalents	10.82	(7.93)	9.58	(11.89)
Cash and cash equivalents as at the beginning of the year	16.44	24.37	21.23	33.12
Cash and cash equivalents as at the end of the year	27.26	16.44	30.81	21.23



Astec LifeSciences Limited
Corporate Identity Number : L99999MH1994PLC076236

Registered Office : Godrej One, 3rd Floor, Pirojshanagar, Eastern Express Highway, Vikhroli (East), Mumbai- 400079, Maharashtra
Website: www.astecsl.com, **Tel no.:** 022-25195768, **Fax no.:** 022-22618289, **Email id:** astecinfo@godrejastec.com
Statement of Assets and Liabilities as at 31st March, 2020



(Rs. in Lakh)

PARTICULARS	STANDALONE		CONSOLIDATED	
	As at	As at	As at	As at
	31st March, 2020	31st March, 2019	31st March, 2020	31st March, 2019
	(Audited)	(Audited)	(Audited)	(Audited)
ASSETS				
(1) Non-current assets				
(a) Property, Plant and Equipment	17,747.43	16,457.64	17,772.40	16,488.23
(b) Capital work-in-progress	2,211.22	1,863.24	2,211.22	1,863.24
(c) Investment property	-	-	-	-
(d) Right of use	1,463.75	-	1,433.17	-
(e) Other Intangible assets	156.86	206.71	156.86	206.71
(f) Intangible assets under development	199.52	34.74	199.52	34.74
(g) Biological Assets other than bearer plants	-	-	-	-
(f) Investments in Subsidiaries	48.89	48.89	-	-
(g) Financial Assets				
(i) Investments	0.53	0.53	0.53	0.53
(ii) Trade receivables	-	-	-	-
(ii) Loans	244.28	245.25	254.40	255.37
(ii) Others	-	-	-	-
(h) Other Tax assets (net)	351.55	217.24	351.55	217.21
(h) Deferred tax assets (net)	-	-	-	-
(i) Other non-current assets	1,617.07	2,194.42	1,617.07	2,194.42
Total Non-current assets	24,041.10	21,268.66	23,996.72	21,260.45
(2) Current Assets				
(a) Inventories	12,117.06	9,284.95	12,117.06	9,284.95
(b) Financial Assets				
(i) Investments	-	-	-	-
(ii) Trade Receivables	16,083.06	12,179.58	16,084.49	12,180.93
(iii) Cash and cash equivalents	27.26	16.44	30.81	21.23
(iv) Bank balances other than (iii) above	117.97	126.90	117.97	126.90
(v) Loans	2,890.57	4.85	2,890.57	4.85
(vi) Others	473.35	26.34	473.35	26.34
(c) Other current assets	1,459.38	3,200.87	1,460.87	3,202.56
Total Current Assets	33,168.65	24,839.93	33,175.12	24,847.76
Total Assets	57,209.75	46,108.59	57,171.84	46,108.21
EQUITY AND LIABILITIES				
Equity				
(a) Equity Share capital	1,956.84	1,955.27	1,956.84	1,955.27
(b) Other Equity	22,687.06	18,291.22	22,699.74	18,293.38
(c) Non controlling interest	-	-	32.85	31.25
Total Equity	24,643.90	20,246.49	24,689.43	20,279.90
LIABILITIES				
(1) Non-current liabilities				
(a) Financial Liabilities				
(i) Lease liability	36.16	-	-	-
(b) Provisions	32.02	22.86	32.02	22.86
(c) Deferred tax liabilities (net)	609.50	922.95	614.10	925.02
Total Non Current Liabilities	677.68	945.81	646.12	947.88
(2) Current Liabilities				
(a) Financial Liabilities				
(i) Borrowings	9,871.16	17,566.79	9,871.16	17,566.79
(ii) Trade payables				
Total outstanding dues from Micro, Small and Medium Enterprises	11.91	102.64	11.91	102.64
Total outstanding dues from other than Micro, Small and Medium Enterprises	20,275.10	6,261.58	20,227.05	6,222.80
(iii) Other financial liabilities	1,584.37	893.03	1,579.06	894.94
(b) Other current liabilities	91.20	55.76	92.68	56.77
(c) Provisions	54.43	36.49	54.43	36.49
Total Current Liabilities	31,888.17	24,916.29	31,836.29	24,880.43
Total Equity and Liabilities	57,209.75	46,108.59	57,171.84	46,108.21

For Astec LifeSciences Limited

Ashok Hiremath
Managing Director
DIN :- 00349345
Tuesday, 5th May, 2020, Mumbai

B S R & Co. LLP

Chartered Accountants

5th Floor, Lodha Excelus,
Apollo Mills Compound
N. M. Joshi Marg, Mahalaxmi
Mumbai - 400 011
India

Telephone +91 (22) 4345 5300
Fax +91 (22) 4345 5399

Independent Auditors' Report

To The Board of Directors of Astec LifeSciences Limited.

Report on the audit of the Standalone Annual Financial Results

Opinion

We have audited the accompanying standalone annual financial results of Astec LifeSciences Limited Company Limited (hereinafter referred to as the "Company") for the year ended 31 March 2020, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone annual financial results:

- a. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- b. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards, and other accounting principles generally accepted in India, of the net profit and other comprehensive income and other financial information for the year ended 31 March 2020.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those SAs are further described in the *Auditor's Responsibilities for the Audit of the Standalone Annual Financial Results* section of our report. We are independent of the Company, in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act, and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained, is sufficient and appropriate to provide a basis for our opinion on the Standalone annual financial results.

Management's and Board of Directors' Responsibilities for the Standalone Annual Financial Results

These standalone annual financial results have been prepared on the basis of the standalone annual financial statements.

Independent Auditors' Report (*Continued*)

Astec LifeSciences Limited.

Management's and Board of Directors' Responsibilities for the Standalone Annual Financial Results (*Continued*)

The Company's Management and the Board of Directors are responsible for the preparation and presentation of these standalone annual financial results that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standards prescribed under Section 133 of the Act and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone annual financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone annual financial results, the Management and the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Annual Financial Results

Our objectives are to obtain reasonable assurance about whether the standalone annual financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone annual financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone annual financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of financial statements on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.

Independent Auditors' Report (*Continued*)

Astec LifeSciences Limited.

Auditor's Responsibilities for the Audit of the Standalone Annual Financial Results (*Continued*)

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures in the standalone financial results made by the Management and Board of Directors.
- Conclude on the appropriateness of the Management and Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the appropriateness of this assumption. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone annual financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone annual financial results, including the disclosures, and whether the standalone annual financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matters

The standalone annual financial results include the results for the quarter ended 31 March 2020 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

For B S R & Co. LLP

Chartered Accountants

Firm's Registration No: 101248W/W-100022

Burjis Pardiwala

Partner

Mumbai
5 May 2020

Membership Number: 103595
UDIN: 20103595AAAABE9353

B S R & Co. LLP

Chartered Accountants

5th Floor, Lodha Excelus,
Apollo Mills Compound
N. M. Joshi Marg, Mahalaxmi
Mumbai - 400 011
India

Telephone +91 (22) 4345 5300
Fax +91 (22) 4345 5399

Independent Auditors' Report

To The Board of Directors of Astec LifeSciences Limited

Report on the audit of the Consolidated Annual Financial Results

Opinion

We have audited the accompanying consolidated annual financial results of Astec LifeSciences Limited (hereinafter referred to as the "Holding Company") and its subsidiaries (Holding Company and its subsidiaries together referred to as "the Group") for the year ended 31 March 2020, attached herewith, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us and based on the consideration of report of other auditors on separate audited financial statements / financial information of the subsidiaries referred to in other matters paragraph below, the aforesaid consolidated annual financial results:

- a. include the annual financial results/ financial information of the following entities:
 - i. Behram Chemicals Private Limited
 - ii. Astec Europe SPRL
 - iii. Comercializadora Agricola Agroastrachem CIA LTDA
- b. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- c. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards, and other accounting principles generally accepted in India, of consolidated net profit and other comprehensive income and other financial information of the Group for the year ended 31 March 2020.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those SAs are further described in the *Auditor's Responsibilities for the Audit of the Consolidated Annual Financial Results* section of our report. We are independent of the Group in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act, and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us along with the consideration of audit reports of the other auditors referred to in sub paragraph (a) of the "Other Matters" paragraph below, is sufficient and appropriate to provide a basis for our opinion on the consolidated annual financial results.

Independent Auditors' Report (*Continued*)

Astec LifeSciences Limited

Management's and Board of Directors' Responsibilities for the Consolidated Annual Financial Results

These consolidated annual financial results have been prepared on the basis of the consolidated annual financial statements.

The Holding Company's Management and the Board of Directors are responsible for the preparation and presentation of these consolidated annual financial results that give a true and fair view of the consolidated net profit and other comprehensive income and other financial information of the Group in accordance with the recognition and measurement principles laid down in Indian Accounting Standards prescribed under Section 133 of the Act and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The respective Management and Board of Directors of the companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of each company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the consolidated annual financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated annual financial results by the Management and the Directors of the Holding Company, as aforesaid.

In preparing the consolidated annual financial results, the Management and the respective Board of Directors of the companies included in the Group are responsible for assessing the ability of each company to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the company or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group is responsible for overseeing the financial reporting process of each company.

Auditor's Responsibilities for the Audit of the Consolidated Annual Financial Results

Our objectives are to obtain reasonable assurance about whether the consolidated annual financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated annual financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated annual financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

Independent Auditors' Report (*Continued*)

Astec LifeSciences Limited

Auditor's Responsibilities for the Audit of the Consolidated Annual Financial Results (*Continued*)

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of financial statements on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures in the consolidated financial results made by the Management and Board of Directors.
- Conclude on the appropriateness of the Management and Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the appropriateness of this assumption. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated annual financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated annual financial results, including the disclosures, and whether the consolidated annual financial results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial results/financial information of the entities within the Group to express an opinion on the consolidated annual financial results. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the consolidated financial results of which we are the independent auditors. For the other entities included in the consolidated annual financial results, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion. Our responsibilities in this regard are further described in para (a) of the section titled "Other Matters" in this audit report.

We communicate with those charged with governance of the Holding Company and such other entities included in the consolidated annual financial results of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the circular No CIR/CFD/CMD1/44/2019 issued by the SEBI under Regulation 33(8) of the Listing Regulations, as amended, to the extent applicable.

Independent Auditors' Report (*Continued*)

Astec LifeSciences Limited

Other Matters

- (a) The consolidated annual financial results include the audited financial results of a subsidiary, whose financial results reflect total assets (before consolidation adjustments) of Rs.103.34 Lakhs as at 31 March 2020, total revenue (before consolidation adjustments) of Rs.10.80 Lakhs and total net profit after tax (before consolidation adjustments) of Rs. 6.24 Lakhs and net cash inflows of Rs 0.00 Lakhs for the year ended on that date, as considered in the consolidated annual financial results, which have been audited by their independent auditors. The independent auditors' report on financial results of this entity has been furnished to us by the management and our opinion on the consolidated annual financial results, in so far as it relates to the amounts and disclosures included in respect of this entity, is based solely on the report of such auditors and the procedures performed by us are as stated in paragraph above.
- (b) The consolidated annual financial results include the unaudited financial information of two subsidiaries, whose financial information reflect total assets (before consolidation adjustments) of Rs. 5.72 Lakhs as at 31 March 2020, total revenue (before consolidation adjustments) of Rs. 38.52 Lakhs and total net (loss) after tax (before consolidation adjustments) of Rs. (1.09) lakhs, and net cash (outflows) of Rs. (1.24) Lakhs for the year ended on that date, as considered in the consolidated annual financial results. These unaudited financial information have been furnished to us by the Board of Directors and our opinion on the consolidated annual financial results, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on such financial information. In our opinion and according to the information and explanations given to us by the Board of Directors, these financial information are not material to the Group.

Our opinion on the consolidated annual financial results is not modified in respect of the above matters with respect to our reliance on the work done and the report of the other auditors and the financial information certified by the Board of Directors.

- (c) The consolidated annual financial results include the results for the quarter ended 31 March 2020 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

For B S R & Co. LLP

Chartered Accountants

Firm's Registration No: 101248W/W-100022

Burjis Pardiwala

Partner

Mumbai
5 May 2020

Membership No: 103595
UDIN: 20103595AAAABF8002